Zimbabwe has declined a significant US healthcare agreement valued at $367m (£272m) over five years over the United States' demand for sensitive data.
This move was revealed following a internal memorandum from December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesman has since clarified that the United States was seeking health data for research and commercial purposes but refused to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable process of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for continued talks to secure a deal agreeable to both sides so the country's vital HIV treatment initiative can be sustained.
Wider Implications
Zimbabwe's decision comes after a similar case in Kenya, where a high court blocked a related deal with the US following concerns were raised about the safety of citizens' medical information.
After returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had managed assistance for the US government, but Trump stated its spending was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
According to statements, 16 African countries have so far signed similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment through American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no corresponding guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"Put simply, our country would provide the raw materials for medical research without any certainty that the final treatments would be accessible to our people should a future pandemic arise."
National Interest and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending frameworks previously set up through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to deal with potential global health emergencies.
"This framework is designed to guarantee that when a nation provides its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
These objections regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent collaboration might be structured in a way that honours the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but urged that talks need to persist since a large portion of the country's HIV programmes were funded by external financing.
"Where specific concerns exist, including those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," it said.
The halted deal emphasises the complex tensions between accepting much-needed international aid and protecting a country's data in an increasingly data-driven world.